300158 振东制药
已收盘 07-22 15:00:00
资讯
新帖
简况
7月17日振东制药涨5.41%,鹏华高质量增长混合A基金重仓该股
证券之星 · 07-17
7月17日振东制药涨5.41%,鹏华高质量增长混合A基金重仓该股
7月5日振东制药涨5.28%,鹏华高质量增长混合A基金重仓该股
证券之星 · 07-05
7月5日振东制药涨5.28%,鹏华高质量增长混合A基金重仓该股
振东制药(300158)7月1日主力资金净买入1556.53万元
证券之星 · 07-02
振东制药(300158)7月1日主力资金净买入1556.53万元
振东制药(300158)股东山西振东健康产业集团有限公司质押3605万股,占总股本3.51%
证券之星 · 07-01
振东制药(300158)股东山西振东健康产业集团有限公司质押3605万股,占总股本3.51%
7月1日振东制药涨5.24%,鹏华高质量增长混合A基金重仓该股
证券之星 · 07-01
7月1日振东制药涨5.24%,鹏华高质量增长混合A基金重仓该股
振东制药:控股股东振东集团合计解押股数为445万股,合计质押股数为3147万股
金融界 · 06-25
振东制药:控股股东振东集团合计解押股数为445万股,合计质押股数为3147万股
振东制药:控股股东解除质押855万股 占公司总股本比例0.83%
中国财富通 · 06-18
振东制药:控股股东解除质押855万股 占公司总股本比例0.83%
振东制药:公司与九芝堂并非同一实际控制人
证券之星 · 06-05
振东制药:公司与九芝堂并非同一实际控制人
振东制药(300158)5月21日主力资金净卖出3272.34万元
证券之星 · 05-22
振东制药(300158)5月21日主力资金净卖出3272.34万元
大跌逾5%!振东制药销售费用高企被追问
资本秘闻 · 05-21
大跌逾5%!振东制药销售费用高企被追问
5月21日振东制药跌5.48%,鹏华高质量增长混合A基金重仓该股
证券之星 · 05-21
5月21日振东制药跌5.48%,鹏华高质量增长混合A基金重仓该股
振东制药收深交所年报问询函,涉及应收账款、关联交易等问题
证券之星 · 05-20
振东制药收深交所年报问询函,涉及应收账款、关联交易等问题
振东制药(300158)股东山西振东健康产业集团有限公司质押1050万股,占总股本1.03%
证券之星 · 05-15
振东制药(300158)股东山西振东健康产业集团有限公司质押1050万股,占总股本1.03%
振东制药(300158.SZ)累计回购2.16%股份 耗资1.03亿元
智通财经网 · 05-06
振东制药(300158.SZ)累计回购2.16%股份 耗资1.03亿元
振东制药(300158)股东山西振东健康产业集团有限公司质押1105万股,占总股本1.08%
证券之星 · 04-29
振东制药(300158)股东山西振东健康产业集团有限公司质押1105万股,占总股本1.08%
振东制药(300158)4月23日主力资金净买入808.42万元
证券之星 · 04-24
振东制药(300158)4月23日主力资金净买入808.42万元
图解振东制药一季报:第一季度单季净利润同比增5952.52%
证券之星 · 04-23
图解振东制药一季报:第一季度单季净利润同比增5952.52%
振东制药最新公告:一季度净利润2310.16万元 同比扭亏
证券之星 · 04-22
振东制药最新公告:一季度净利润2310.16万元 同比扭亏
振东制药(300158.SZ)发布一季度业绩,净利润2310.16万元,扭亏为盈
智通财经 · 04-22
振东制药(300158.SZ)发布一季度业绩,净利润2310.16万元,扭亏为盈
振东制药(300158.SZ)发布2023年度业绩,净亏损4398.41万元
智通财经 · 04-22
振东制药(300158.SZ)发布2023年度业绩,净亏损4398.41万元
公司概况
公司名称:
山西振东制药股份有限公司
所属行业:
医药制造业
上市日期:
2011-01-07
主营业务:
山西振东制药股份有限公司肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司的主要产品为消化系统药、呼吸系统类用药、泌尿系统药、心脑血管药、抗肿瘤药、血液造血系统药、补益药、抗感染药、皮肤病用药。2022年全国医药工业信息年会公布2021年度全国医药工业百强榜,公司位列第64位。2023年米思会上发布的2022年度中国化药企业TOP100排行榜中,公司位列第52位。公司在2022-2023年度中国医药行业最具影响力榜单评选中获得“医药制造业百强”称号。公司技术中心在2022年被认定为“国家企业中心”,是山西省2022年唯一通过国家认定的企业技术中心。
发行价格:
38.80
{"stockData":{"symbol":"300158","market":"SZ","secType":"STK","nameCN":"振东制药","latestPrice":4,"timestamp":1721631822000,"preClose":3.99,"halted":0,"volume":12208842,"delay":0,"floatShares":1001000000,"shares":1005000000,"eps":-0.0204,"marketStatus":"已收盘","marketStatusCode":5,"change":0.01,"latestTime":"07-22 15:00:00","open":3.96,"high":4.01,"low":3.92,"amount":48505600,"amplitude":0.0226,"askPrice":4,"askSize":337,"bidPrice":3.99,"bidSize":1700,"shortable":0,"etf":0,"ttmEps":-0.0204,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"adjPreClose":3.99,"symbolType":"stock","openAndCloseTimeList":[[1721611800000,1721619000000],[1721624400000,1721631600000]],"highLimit":4.39,"lowLimit":3.59,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1005319756,"pbRate":0.78,"roa":"--","roe":"0.45%","epsLYR":-0.0428,"committee":0.170621,"marketValue":4021000000,"floatMarketCap":4005000000,"peRate":-196.078424,"changeRate":0.0025,"turnoverRate":0.0122,"status":0},"requestUrl":"/m/hq/s/300158/wiki","defaultTab":"wiki","newsList":[{"id":"2452820331","title":"7月17日振东制药涨5.41%,鹏华高质量增长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452820331","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452820331?lang=zh_cn&edition=full","pubTime":"2024-07-17 16:22","pubTimestamp":1721204569,"startTime":"0","endTime":"0","summary":"证券之星消息,7月17日振东制药涨5.41%,收盘报4.09元,换手率3.56%,成交量35.64万手,成交额1.44亿元。重仓振东制药的公募基金请见下表:根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共4家,其中持有数量最多的公募基金为鹏华高质量增长混合A。鹏华高质量增长混合A目前规模为9.44亿元,最新净值0.5957,较上一交易日上涨0.86%,近一年下跌27.59%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071700032638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0186","BK0239","BK0060"],"gpt_icon":0},{"id":"2449925388","title":"7月5日振东制药涨5.28%,鹏华高质量增长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449925388","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449925388?lang=zh_cn&edition=full","pubTime":"2024-07-05 16:17","pubTimestamp":1720167459,"startTime":"0","endTime":"0","summary":"证券之星消息,7月5日振东制药涨5.28%,收盘报3.99元,换手率2.39%,成交量24.48万手,成交额9578.92万元。融资融券方面近5日融资净流入261.19万,融资余额增加;融券净流入9000.0,融券余额增加。重仓振东制药的公募基金请见下表:根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共4家,其中持有数量最多的公募基金为鹏华高质量增长混合A。鹏华高质量增长混合A目前规模为9.44亿元,最新净值0.5667,较上一交易日下跌1.27%,近一年下跌33.24%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500029630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0186","300158","BK0060"],"gpt_icon":0},{"id":"2448973780","title":"振东制药(300158)7月1日主力资金净买入1556.53万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448973780","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448973780?lang=zh_cn&edition=full","pubTime":"2024-07-02 09:13","pubTimestamp":1719882790,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月1日收盘,振东制药报收于4.02元,上涨5.24%,换手率2.4%,成交量24.55万手,成交额9644.13万元。近5日资金流向一览见下表:振东制药融资融券信息显示,融资方面,当日融资买入502.2万元,融资偿还492.06万元,融资净买入10.14万元。振东制药主营业务:肿瘤、毛发、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070200006412.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0186","300158"],"gpt_icon":0},{"id":"2448918505","title":"振东制药(300158)股东山西振东健康产业集团有限公司质押3605万股,占总股本3.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448918505","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448918505?lang=zh_cn&edition=full","pubTime":"2024-07-01 21:25","pubTimestamp":1719840335,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药7月1日公开信息显示,股东山西振东健康产业集团有限公司向中国银行股份有限公司长治市分行合计质押3605.0万股,占总股本3.51%。质押详情见下表:截止本公告日,股东山西振东健康产业集团有限公司已累计质押股份1.99亿股,占其持股总数的65.76%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070100030107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","300158","BK0239","BK0060"],"gpt_icon":0},{"id":"2448963191","title":"7月1日振东制药涨5.24%,鹏华高质量增长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448963191","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448963191?lang=zh_cn&edition=full","pubTime":"2024-07-01 16:14","pubTimestamp":1719821644,"startTime":"0","endTime":"0","summary":"证券之星消息,7月1日振东制药涨5.24%,收盘报4.02元,换手率2.4%,成交量24.55万手,成交额9644.13万元。融资融券方面近5日融资净流入62.23万,融资余额增加;融券净流出3300.0,融券余额减少。重仓振东制药的公募基金请见下表:根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共4家,其中持有数量最多的公募基金为鹏华高质量增长混合A。鹏华高质量增长混合A目前规模为9.44亿元,最新净值0.5799,较上一交易日上涨0.0%,近一年下跌31.74%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070100020191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0060","BK0186","BK0239"],"gpt_icon":0},{"id":"2446407608","title":"振东制药:控股股东振东集团合计解押股数为445万股,合计质押股数为3147万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446407608","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446407608?lang=zh_cn&edition=full","pubTime":"2024-06-25 22:49","pubTimestamp":1719326977,"startTime":"0","endTime":"0","summary":"振东制药 公告,近日接到控股股东山西振东健康产业集团通知,其解押了250万股和195万股,合计解押股数为445万股,占其所持股份比例1.47%,占公司总股本比例0.43%。同时,振东集团完成新质押,质押股数分别为1019万股、564万股、440万股、423万股、387万股、232万股和 82万股,合计质押股数为3147万股,占其所持股份比例10.41%,占公司总股本比例3.06%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062522580895d6e112&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062522580895d6e112&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0015","BK0239","BK0183","BK0278","BK0012","BK0188","BK0186","300158","BK0028","03988","601988","BK0060"],"gpt_icon":0},{"id":"2444810503","title":"振东制药:控股股东解除质押855万股 占公司总股本比例0.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2444810503","media":"中国财富通","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444810503?lang=zh_cn&edition=full","pubTime":"2024-06-18 16:39","pubTimestamp":1718699988,"startTime":"0","endTime":"0","summary":"中国财富通6月18日 - 振东制药(300158)公告称,公司于近日接到控股股东山西振东健康产业集团有限公司通知,获悉其所持有的本公司部分股份办理了解除质押业务,本次解除质押股数855万股,占公司总股本比例0.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=vkzRclDIvZI%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0186","300158","BK0239","BK0060"],"gpt_icon":0},{"id":"2441247276","title":"振东制药:公司与九芝堂并非同一实际控制人","url":"https://stock-news.laohu8.com/highlight/detail?id=2441247276","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441247276?lang=zh_cn&edition=full","pubTime":"2024-06-05 17:02","pubTimestamp":1717578178,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药(300158)06月05日在投资者关系平台上答复投资者关心的问题。投资者:请问公司和九芝堂是同一实控人吗?振东制药董秘:尊敬的投资者您好!公司与九芝堂并非同一实际控制人。感谢您的关注!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060500034303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","300158","BK0239","BK0060"],"gpt_icon":0},{"id":"2437402087","title":"振东制药(300158)5月21日主力资金净卖出3272.34万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2437402087","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437402087?lang=zh_cn&edition=full","pubTime":"2024-05-22 09:46","pubTimestamp":1716342389,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月21日收盘,振东制药报收于4.66元,下跌5.48%,换手率4.98%,成交量50.95万手,成交额2.34亿元。近5日资金流向一览见下表:振东制药融资融券信息显示,融资方面,当日融资买入1164.38万元,融资偿还1341.3万元,融资净偿还176.92万元。振东制药主营业务:肿瘤、毛发、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052200015616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0239","BK0186","BK0060"],"gpt_icon":0},{"id":"2437412246","title":"大跌逾5%!振东制药销售费用高企被追问","url":"https://stock-news.laohu8.com/highlight/detail?id=2437412246","media":"资本秘闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437412246?lang=zh_cn&edition=full","pubTime":"2024-05-21 20:40","pubTimestamp":1716295200,"startTime":"0","endTime":"0","summary":"股价下跌背后,5月20日晚间,振东制药收到了深交所下发的年报问询函,而这已是公司自2019年年报遭问询以来,连续第五年收到年报问询函。收到年报问询函的振东制药,2023年归属净利润继续出现亏损。在年报问询函中,深交所重点关注了振东制药销售费用的问题。财务数据显示,2023年,振东制药销售费用14.76亿元,其中服务费、市场运营费10.53亿元,职工薪酬2.16亿元,同比增加5495.84万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-05-21/doc-inavyzef5352407.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-05-21/doc-inavyzef5352407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0060","BK0239","BK0186","300158"],"gpt_icon":0},{"id":"2437493467","title":"5月21日振东制药跌5.48%,鹏华高质量增长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2437493467","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437493467?lang=zh_cn&edition=full","pubTime":"2024-05-21 16:12","pubTimestamp":1716279162,"startTime":"0","endTime":"0","summary":"证券之星消息,5月21日振东制药跌5.48%,收盘报4.66元,换手率4.98%,成交量50.95万手,成交额2.34亿元。融资融券方面近5日融资净流出1581.35万,融资余额减少;融券净流出13.48万,融券余额减少。重仓振东制药的公募基金请见下表:根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共4家,其中持有数量最多的公募基金为鹏华高质量增长混合A。鹏华高质量增长混合A目前规模为9.44亿元,最新净值0.6219,较上一交易日上涨0.29%,近一年下跌20.77%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052100025884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300158","BK0186"],"gpt_icon":0},{"id":"2436178347","title":"振东制药收深交所年报问询函,涉及应收账款、关联交易等问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2436178347","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436178347?lang=zh_cn&edition=full","pubTime":"2024-05-20 17:37","pubTimestamp":1716197837,"startTime":"0","endTime":"0","summary":"5月20日,振东制药收到了深圳证券交易所关于其2023年年报问询函。问询函涉及银行存款因担保事项权利受限、应收账款、关联交易等问题。深交所要求该公司就相关问题做出书面说明,在2024年6月3日前将有关说明材料报送深交所并对外披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024052000019181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0239","BK0186","BK0060"],"gpt_icon":0},{"id":"2435653517","title":"振东制药(300158)股东山西振东健康产业集团有限公司质押1050万股,占总股本1.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2435653517","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435653517?lang=zh_cn&edition=full","pubTime":"2024-05-15 21:36","pubTimestamp":1715780210,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药5月15日公开信息显示,股东山西振东健康产业集团有限公司向中国银行股份有限公司长治市分行合计质押1050.0万股,占总股本1.03%。质押详情见下表:截止本公告日,股东山西振东健康产业集团有限公司已累计质押股份1.78亿股,占其持股总数的59.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051500037608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300158","BK0186","BK0239"],"gpt_icon":0},{"id":"2433196428","title":"振东制药(300158.SZ)累计回购2.16%股份 耗资1.03亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433196428","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433196428?lang=zh_cn&edition=full","pubTime":"2024-05-06 18:29","pubTimestamp":1714991347,"startTime":"0","endTime":"0","summary":"振东制药(300158.SZ)公告,公司回购已实施完毕,截至2024年4月30日,...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/astock/5.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/5.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1117681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300158","BK0060","BK0239","BK0186"],"gpt_icon":0},{"id":"2431786524","title":"振东制药(300158)股东山西振东健康产业集团有限公司质押1105万股,占总股本1.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431786524","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431786524?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:36","pubTimestamp":1714397799,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药4月29日公开信息显示,股东山西振东健康产业集团有限公司向中国银行股份有限公司长治市分行合计质押1105.0万股,占总股本1.08%。质押详情见下表:截止本公告日,股东山西振东健康产业集团有限公司已累计质押股份1.81亿股,占其持股总数的59.99%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900032444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0239","BK0060","BK0186"],"gpt_icon":0},{"id":"2429124178","title":"振东制药(300158)4月23日主力资金净买入808.42万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429124178","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429124178?lang=zh_cn&edition=full","pubTime":"2024-04-24 09:15","pubTimestamp":1713921327,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年4月23日收盘,振东制药报收于4.34元,上涨4.33%,换手率3.35%,成交量34.27万手,成交额1.48亿元。近5日资金流向一览见下表:振东制药融资融券信息显示,融资方面,当日融资买入716.6万元,融资偿还616.69万元,融资净买入99.91万元。振东制药主营业务:肿瘤、毛发、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400018343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300158","BK0186","BK0060"],"gpt_icon":0},{"id":"2429974208","title":"图解振东制药一季报:第一季度单季净利润同比增5952.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429974208","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429974208?lang=zh_cn&edition=full","pubTime":"2024-04-23 01:37","pubTimestamp":1713807426,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药2024年一季报显示,公司主营收入7.82亿元,同比下降17.79%;归母净利润2310.16万元,同比上升5952.52%;扣非净利润-859.24万元,同比上升51.35%;负债率15.08%,投资收益1688.88万元,财务费用-44.9万元,毛利率44.39%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300002122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158"],"gpt_icon":0},{"id":"2429949065","title":"振东制药最新公告:一季度净利润2310.16万元 同比扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2429949065","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429949065?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:40","pubTimestamp":1713782453,"startTime":"0","endTime":"0","summary":"振东制药公布2024年一季度报告,报告期营业收入7.82亿元,同比下降17.79%;归属于上市公司股东的净利润2310.16万元,同比扭亏为盈。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200022334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158"],"gpt_icon":0},{"id":"2429011945","title":"振东制药(300158.SZ)发布一季度业绩,净利润2310.16万元,扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2429011945","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429011945?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:14","pubTimestamp":1713780895,"startTime":"0","endTime":"0","summary":"智通财经APP讯,振东制药(300158.SZ)发布2024年第一季度报告,公司营业收入7.82亿元,同比下降17.79%;归属于上市公司股东的净利润2310.16万元,扭亏为盈;归属于上市公司股东的扣除非经常性损益的净亏损859.24万元,亏损收窄;基本每股收益0.0225元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300158"],"gpt_icon":0},{"id":"2429945715","title":"振东制药(300158.SZ)发布2023年度业绩,净亏损4398.41万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429945715","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429945715?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:12","pubTimestamp":1713780753,"startTime":"0","endTime":"0","summary":"智通财经APP讯,振东制药(300158.SZ)发布2023年年度报告,报告期内,公司实现营业收入36.26亿元,同比下降2.75%。归属于上市公司股东的净亏损4398.41万元,归属于上市公司股东的扣除非经常性损益的净亏损1.16亿元,基本每股亏损0.0428元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300158","BK0239","BK0060","BK0186"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-01-07","address":"山西省长治市上党区光明南路振东科技园","stockEarnings":[{"period":"1week","weight":0.0309},{"period":"1month","weight":0.0204},{"period":"3month","weight":-0.0783},{"period":"6month","weight":-0.2126},{"period":"1year","weight":-0.3068},{"period":"ytd","weight":-0.4074}],"companyName":"山西振东制药股份有限公司","boardCode":"AI0027","perCapita":"18605股","boardName":"医药制造业","registeredCapital":"100531万元","compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.0191},{"period":"6month","weight":0.0509},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":-0.0036}],"survey":" 山西振东制药股份有限公司肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司的主要产品为消化系统药、呼吸系统类用药、泌尿系统药、心脑血管药、抗肿瘤药、血液造血系统药、补益药、抗感染药、皮肤病用药。2022年全国医药工业信息年会公布2021年度全国医药工业百强榜,公司位列第64位。2023年米思会上发布的2022年度中国化药企业TOP100排行榜中,公司位列第52位。公司在2022-2023年度中国医药行业最具影响力榜单评选中获得“医药制造业百强”称号。公司技术中心在2022年被认定为“国家企业中心”,是山西省2022年唯一通过国家认定的企业技术中心。","serverTime":1721672455070,"listedPrice":38.8,"stockholders":"53808人(较上一季度增加0.34%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"振东制药,300158,振东制药股票,振东制药股票老虎,振东制药股票老虎国际,振东制药行情,振东制药股票行情,振东制药股价,振东制药股市,振东制药股票价格,振东制药股票交易,振东制药股票购买,振东制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}